Type I interferon is selectively required by dendritic cells for immune rejection of tumors

By Mark S. Diamond, M. Kinder, H. Matsushita, M. Mashayekhi, G. Dunn, Jessica M. Archambault, Hsiaoju S Lee, C. Arthur, J. White, U. Kalinke and 2 more. Journal of Experimental Medicine, 2011

1,089 citations recorded by the source corpus.

Dendritic cell responsiveness to type I interferon is required for the generation of antitumor T cell responses and tumor rejection.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/579a211cc850b32e238ad3d052025d0aa6ab30d4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

Citations in the corpus

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy (2014, background): “The presence of TILs in tumors has been shown to be associatedwith type I IFN transcriptional profile, and additional studies demonstrated the critical role for type I IFN in CD8a DCmediated antigen cross-presentation and priming of tumor-specific CD8 T cells (8, 9).”
Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells (2015, neutral): “Second, the local delivery of IFNb as ‘‘Signal 3’’ could enhance tumor eradication inmultiple ways, by enhancing cross-priming activity of DCs (Diamond et al., 2011; Fuertes et al., 2011; Yang et al., 2014), inhibiting Treg activation and proliferation (Golding et al.”
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors (2014, background): “We therefore pursued a working model in which innate immune sensing pathways might detect tumor-derived factors, induce type I IFN production, and lead to cross-priming of tumor antigen-specific CD8+ T cells (Diamond et al., 2011; Fuertes et al., 2011).”
Dendritic Cells and Cancer Immunity (2016, background): “Type I IFNs (IFN-α, IFN-β) promote DC activation, migration and cross-presentation, and in an elegant series of experiments IFNAR1 expression by Batf3dependent cDC1 was found to be specifically required [6, 46].”
Roles of the immune system in cancer: from tumor initiation to metastatic progression (2018, background): “This anti-tumor effect of CD8a + DCs priming effector T cells is selectively dependent on type I interferon production (Diamond et al. 2011).”
IDO in the Tumor Microenvironment: Inflammation, Counter-regulation and Tolerance (2016, neutral): “As discussed above, DNA sensing to activate STING/IFNαβ signaling slowed growth of immunogenic tumors and potentiated tumor regression after therapy [63, 72-74].”
The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer (2018, background): “The activation of APCs requires type I IFN signaling initiated by innate immune sensors (Diamond et al., 2011; Fuertes et al., 2011).”
Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma (2016, neutral): “Indeed, the previous studies that promoted CD8a+ DC as the critical cells for priming T cells in spleen noted that such priming required signaling through type I interferon (Diamond et al., 2011; Fuertes et al., 2011).”
New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape (2014, neutral): “Type I IFN sensitivity in granulocytes, macrophages and NK cells, all of which express type I IFN receptors, was not required for tumour rejection [18].”